Roth Capital Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $40

Benzinga Newsdesk www.benzinga.com Neutral 57.1%

Neg 0% Neu 57.1% Pos 0%

Roth Capital analyst Max Masucci initiates coverage on Castle Biosciences (NASDAQ:CSTL) with a Buy rating and announces Price Target of $40.